Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,769,672
  • Shares Outstanding, K 93,944
  • Annual Sales, $ 1,046 M
  • Annual Income, $ 407,300 K
  • 60-Month Beta 0.79
  • Price/Sales 8.33
  • Price/Cash Flow 19.91
  • Price/Book 7.73
Trade NBIX with:

Options Overview

Details
  • Implied Volatility 42.68%
  • Historical Volatility 55.76%
  • IV Percentile 20%
  • IV Rank 18.10%
  • IV High 62.16% on 10/20/20
  • IV Low 38.38% on 05/08/20
  • Put/Call Vol Ratio 0.11
  • Today's Volume 203
  • Volume Avg (30-Day) 423
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 5,446
  • Open Int (30-Day) 4,984

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.51
  • Number of Estimates 12
  • High Estimate 0.81
  • Low Estimate 0.11
  • Prior Year 0.82
  • Growth Rate Est. (year over year) -37.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.37 +6.84%
on 03/24/21
102.50 -8.93%
on 03/29/21
+2.34 (+2.57%)
since 03/09/21
3-Month
87.37 +6.84%
on 03/24/21
120.27 -22.38%
on 01/25/21
-18.72 (-16.70%)
since 01/08/21
52-Week
86.02 +8.52%
on 11/19/20
136.26 -31.49%
on 07/09/20
-3.33 (-3.44%)
since 04/09/20

Most Recent Stories

More News
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology's (AAN)...

NBIX : 93.35 (+0.71%)
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?

Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

NBIX : 93.35 (+0.71%)
Late Rally Snaps Market's Two-Day Skid

Late Rally Snaps Market's Two-Day Skid

DT : 52.89 (+0.72%)
AUDC : 30.94 (+1.44%)
KLIC : 54.23 (-3.51%)
NBIX : 93.35 (+0.71%)
AXLA : 4.34 (-5.24%)
ONCT : 8.26 (-11.56%)
GRPN : 48.73 (+0.25%)
REAL : 23.79 (+2.17%)
LQDT : 18.87 (+1.02%)
MOGO : 10.58 (-0.28%)
FLL : 9.50 (+2.26%)
MGNI : 40.18 (+1.57%)
ACLS : 44.33 (-3.02%)
IRDM : 42.95 (+2.16%)
CVET : 28.74 (-1.88%)
Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3 Annual CNS Day at Apr. 1, 2021. Eiry Roberts, Chief Medical Officer, and , Chief Business Development and Strategy...

NBIX : 93.35 (+0.71%)
Thinking about trading options or stock in Cisco Systems, Neurocrine Biosciences, Moderna, Darden Restaurants, or Lumentum Holdings?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CSCO, NBIX, MRNA, DRI, and LITE.

CSCO : 52.09 (+0.35%)
LITE : 91.20 (-0.08%)
MRNA : 140.92 (+5.26%)
NBIX : 93.35 (+0.71%)
DRI : 143.10 (-1.81%)
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600

, /PRNewswire/ -- Neurocrine Biosciences Inc. (NASD:NBIX) will replace O-I Glass Inc. (NYSE:OI) in the S&P MidCap 400, and O-I Glass will replace HMS Holdings Corp (NASD:HMSY) in the S&P SmallCap 600...

NBIX : 93.35 (+0.71%)
OI : 14.68 (+3.23%)
HMSY : 36.97 (unch)
SPGI : 369.10 (+0.95%)
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral,...

NBIX : 93.35 (+0.71%)
Downtrend Call Working As Neurocrine Biosc Stock Falls 11.5% (NBIX)

SmarTrend identified a Downtrend for Neurocrine Biosc (NASDAQ:NBIX) on March 2nd, 2021 at $102.08. In approximately 2 weeks, Neurocrine Biosc has returned 11.55% as of today's recent price of $90.29.

NBIX : 93.35 (+0.71%)
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31 Annual Healthcare Conference at Mar. 16, 2021. , Chief Financial Officer, will present at the conference....

NBIX : 93.35 (+0.71%)
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

, /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in...

NBIX : 93.35 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 96.85
2nd Resistance Point 95.44
1st Resistance Point 94.39
Last Price 93.35
1st Support Level 91.93
2nd Support Level 90.52
3rd Support Level 89.47

See More

52-Week High 136.26
Fibonacci 61.8% 117.07
Fibonacci 50% 111.14
Fibonacci 38.2% 105.21
Last Price 93.35
52-Week Low 86.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar